Alkermes is a biopharmaceutical company. Co. has a portfolio of commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer. Co.'s proprietary products include: ARISTADA, which is an extended-release intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO, which utilizes Co.'s proprietary LinkeRx and NanoCrystal technologies; and LYBALVI, which is an oral atypical antipsychotic drug approved in the U.S. for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder. We show 58 historical shares outstanding datapoints in our ALKS shares outstanding history coverage, used to compute ALKS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ALKS market cap history over the course of time is important for investors
interested in comparing ALKS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ALKS versus a peer is one thing; comparing
ALKS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ALKS can fluctuate over the course of history.
With this page we aim to empower investors researching ALKS by allowing them to research the ALKS market cap history. |
Free ALKS Email Alerts:
Video: The Importance of Market Cap
